Thursday, October 25, 2018 9:22:27 AM
I haven't made up my mind if I want to spend the day listening to the same rhetoric again ..... or if there will be genuine real conversation about what is to take place near term.
Given the history, I expect the same rhetoric and a whole lotta backslapping on the accomplishments of the year with little in the way of meat and potatoes surrounding licensing and commercial launch of KALGAE. As is the case nearly 100% of the time ..... when Dahl speaks .... stock falls. It happened last year after the shareholder meeting however about a week of so later, the stock roughly doubled in price and although a bit of a seesaw, the past year the stock overall has been in an uptrend as evidenced by the 1 year chart in the Ibox above.
Here is a 5 year chart with the MA envelope that better portrays the uptrend of the past year.
http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=zivo&time=12&startdate=1%2F4%2F1999&enddate=10%2F25%2F2018&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=8&uf=4&lf=1&lf2=1024&lf3=4&type=2&style=320&size=4&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=34&y=17
The last 2 Novembers were pretty good in terms of price gains and one could argue technical indications support a move northward here given the volume to the downside of late has been trailing off quite a bit. So not a ton of selling happening but no one really stepping up to buy.
That all said, Dahl's shareholder address each year usually provides a fair number of tidbits of what's to come .... never specifics on "when". Shareholders are usually just left with waiting. But things eventually happen. Unfortunately that strategy doesn't play well for a public company. So I don't think much is missed if not going. The real value in going is meeting other shareholders and visually sizing up mgmt's body language when you get them 1 on 1. That's probably the most valuable.
Anyway .... leaning towards not going unless I hear from a few other shareholders I've kept contact with over the years are interested. Then I might reconsider.
Amigo Mike
Recent ZIVO News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/26/2024 05:36:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/26/2024 12:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 04/09/2024 03:49:14 PM
- Form SCHEDULE 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/14/2024 01:16:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:45:37 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 02/15/2024 01:54:37 PM
- ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study • Business Wire • 02/07/2024 09:54:00 PM
- ZIVO Bioscience Announces Uplisting to OTCQB Market • Business Wire • 01/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:11:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:17:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:12:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 02:29:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:21:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:18:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/30/2023 05:20:31 PM
- ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens • Business Wire • 10/30/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 12:56:59 PM
- ZIVO Bioscience Announces Reverse Stock Split • Business Wire • 10/26/2023 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2023 09:08:51 PM
- ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference • GlobeNewswire Inc. • 10/03/2023 12:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM